

Other indications for Leflunomide

Adults:

→ *Psoriatic arthritis:*

100 mg daily for 3 days then 20 mg daily

→ *BK virus (viremia or nephropathy), in kidney transplant recipients (off-label use; based on limited data):*

Loading dose: 100 mg/day for 5 days; Maintenance: 40 mg/day ^{[1][2]}

or Loading dose: 60 mg/day for 2 days; Maintenance: 20 mg/day ^[3]

→ *Cytomegalovirus disease, in transplant recipients resistant to standard antivirals, adjunctive therapy (off-label use; based on limited data):*

Oral: 100 mg once daily for 3 to 5 days, followed by 20 to 40 mg/day ^{[4][5]}

^{[6][7][8]}

NB: consider adjusting dose based on active metabolite serum concentrations and/or adverse events ^{[4][8]}



- [1] - (Lexi Drugs) (AST-IDCOP) Hirsch, H. H., Randhawa, P. S., & AST Infectious Diseases Community of Practice (2019). BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clinical transplantation*, 33(9), e13528. <https://doi.org/10.1111/ctr.13528>
- [2]- Nesselhauf, N., Strutt, J., & Bastani, B. (2016). Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. *Journal of nephropathology*, 5(1), 34–37. <https://doi.org/10.15171/jnp.2016.06>
- [3]- (Lexi Drugs) Kable, K., Davies, C. D., O'connell, P. J., Chapman, J. R., & Nankivell, B. J. (2017). Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin. *Transplantation direct*, 3(4), e142. <https://doi.org/10.1097/TXD.0000000000000641>
- [4]- (Lexi Drugs) Avery, R. K., Mossad, S. B., Poggio, E., Lard, M., Budev, M., Bolwell, B., Waldman, W. J., Braun, W., Mawhorter, S. D., Fatica, R., Krishnamurthi, V., Young, J. B., Shrestha, R., Stephany, B., Lurain, N., & Yen-Lieberman, B. (2010). Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. *Transplantation*, 90(4), 419–426. <https://doi.org/10.1097/TP.0b013e3181e94106>
- [5]- (Lexi Drugs) Chon, W. J., Kadambi, P. V., Xu, C., Becker, Y. T., Witkowski, P., Pursell, K., Kane, B., & Josephson, M. A. (2015). Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago. *Case reports in nephrology and dialysis*, 5(1), 96–105. <https://doi.org/10.1159/000381470>
- [6]- (Lexi Drugs) Gokarn, A., Toshniwal, A., Pathak, A., Arora, S., Bonda, A., Punatar, S., Nayak, L., Dwivedi, P., Bhat, V., Biswas, S., Kelkar, R., Kannan, S., & Khattri, N. (2019). Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*, 25(9), 1832–1836. <https://doi.org/10.1016/j.bbmt.2019.04.028>
- [7]- (Lexi Drugs) Silva, J. T., Pérez-González, V., Lopez-Medrano, F., Alonso-Moralejo, R., Fernández-Ruiz, M., San-Juan, R., Brañas, P., Folgueira, M. D., Aguado, J. M., & de Pablo-Gafas, A. (2018). Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. *Clinical transplantation*, 32(2), 10.1111/ctr.13176. <https://doi.org/10.1111/ctr.13176>
- [8]- (Lexi Drugs) Wang, E., Jan, A. S., Doan, V. P., Ferguson, J. B., & Yeh, J. C. (2019). Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, 25(7), 1731–1737. <https://doi.org/10.1177/1078155218796188>
https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6369?cesid=apb29GWJ6Nf&searchUrl=%2Ffco%2Faction%2Fsearch%3Fq%3Datg%26t%3Dname%26va%3Datg

